We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys and Roche Expand Therapeutic Antibody Partnership
News

MorphoSys and Roche Expand Therapeutic Antibody Partnership

MorphoSys and Roche Expand Therapeutic Antibody Partnership
News

MorphoSys and Roche Expand Therapeutic Antibody Partnership

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys and Roche Expand Therapeutic Antibody Partnership"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG and Roche have announced a collaboration to develop therapeutic antibodies in oncology.

Expanding on a September 2000 relationship in Alzheimer's disease, Roche will elect target molecules against which MorphoSys will generate antibodies using its proprietary HuCAL GOLD® technology.

"Extending our active alliance shows a positive and constructive working relationship between Roche and MorphoSys," said Peter Hug, Roche's Global Head of Pharma Partnering. "We are pleased to collaborate with a proven partner in a new therapeutic area."

"Expanding our existing partnerships is a high priority for us," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys.

"Roche's commitment to initiating new therapeutic antibody programs with MorphoSys is a clear vote of confidence from an existing partner and validation of the utility of our technology in producing potential drugs."

Under the terms of the agreement, Roche and MorphoSys will collaborate on two new antibody programs in oncology.

Roche will be responsible for preclinical and clinical development as well as subsequent marketing of all resulting products.

MorphoSys will receive an upfront payment and may receive additional research funding and future event payments totaling more than EUR 10 million per program, plus potential royalties.

Advertisement